Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01871714 · ClinicalTrials.gov registry record
Phenotypic Properties in Individuals Affected With XLHED
A clinical trial, sponsored by Edimer Pharmaceuticals.
- Completed
- Registry status
- 30
- Enrollment target
NCT01871714: Completed study, sponsored by Edimer Pharmaceuticals.
NCT01871714 is a clinical trial that has completed, run by Edimer Pharmaceuticals. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01871714 has completed, sponsored by Edimer Pharmaceuticals.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The current study design incorporates two previously developed, non-invasive approaches to characterize the phenotype of individuals affected with XLHED.
Primary Outcome
To collect demographic and clinical status information in XLHED-affected males, adult females at risk for XLHED and adult female controls using a medical questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-05 |
| Est. Completion | 2013-09 |
What the finished NCT01871714 record still lists
NCT01871714 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01871714 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01871714 about?
NCT01871714 is a clinical study titled "Phenotypic Properties in Individuals Affected With XLHED". The current study design incorporates two previously developed, non-invasive approaches to characterize the phenotype of individuals affected with XLHED.
What is the current status of trial NCT01871714?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2013-05. Estimated completion is 2013-09.
Who is sponsoring clinical trial NCT01871714?
This trial is sponsored by Edimer Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia